Logo for Minerva Neurosciences Inc

Minerva Neurosciences Investor Relations Material

Latest events

Logo for Minerva Neurosciences Inc

Q1 2023

Minerva Neurosciences
Logo for Minerva Neurosciences

Q1 2024

1 May, 2024
Logo for Minerva Neurosciences

Q4 2023

22 Feb, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Minerva Neurosciences Inc

Access all reports
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. The company is developing brexanolone (MNRX), which targets all three types of glucocorticoid receptors to treat postpartum depression and infantile spasms in children. It also focuses on the research and development of a pipeline of compounds that modulate GABA receptors or downstream pathways and programs targeting other neurotransmitter systems. Minerva Neurosciences was founded in 2009 and is based in Menlo Park, California.